The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

Puma Biotechnology offers runway stability but lacks clear growth drivers amid drug headwinds and pipeline gaps. Find out why ...

A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common ...

A "landmark moment" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

AstraZeneca to showcase innovation in infectious disease protection at ESCMID Global 2025: Cambridge, UK Thursday, April 10, 2025, 15:00 Hrs [IST] AstraZeneca will share new data ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other institutions, have successfully ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...